Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Pulse may leads to higher death or bronchopulmonary dysplasia at 36 weeks' PMA compared with continuous dexamethasone therapy (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Individual tailored showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with continuous tapered dexamethasone regimen (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Later showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks' PMA compared with earlier initiation of dexamethasone therapy (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants < 37 weeks' gestational age requiring conventional mechanical ventilation for respiratory distress syndrome
Oxygen‐guided lung‐recruitment maneuver showed no clear difference in bronchopulmonary dysplasia compared with routine care (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
Bubble showed no clear difference in bronchopulmonary dysplasia compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants receiving nasal CPAP
It is very uncertain whether mask changes bronchopulmonary dysplasia compared with prongs (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · preterm infants
Enteral zinc supplementation showed no clear difference in bronchopulmonary dysplasia compared with no zinc supplementation (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia · promoting growth and development in very low birth weight infants receiving human milk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia · promoting growth and development in very low birth weight infants receiving human milk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia · promoting growth and development in very low birth weight infants receiving human milk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia · promoting growth and development in very low birth weight infants receiving human milk
It is very uncertain whether targeted or adjustable individualized fortification changes bronchopulmonary dysplasia compared with standard non‐individualized fortification (very low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with surfactant administration via endotracheal tube (ETT) with the… (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via laryngeal mask airway (S‐LMA) showed no clear difference in death or bronchopulmonary dysplasia compared with no surfactant administration (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia at 28 days · preterm infants
It is very uncertain whether prophylactic CPAP changes bronchopulmonary dysplasia at 28 days compared with very early CPAP (very low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia at 28 days · symptomatic patent ductus arteriosus in preterm infants
Indomethacin showed no clear difference in bronchopulmonary dysplasia at 28 days compared with placebo or control (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of bronchopulmonary dysplasia · preterm infants less than 30 weeks' gestational age requiring conventional mechanical ventilation for respiratory distress syndrome
The intervention showed no clear difference in incidence of bronchopulmonary dysplasia (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
MFS‐LE showed no clear difference in bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (low certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · Parenterally fed preterm infants
It is very uncertain whether MS‐LE changes bronchopulmonary dysplasia/chronic lung disease compared with S‐LE (very low certainty).
1 finding from 1 review